Assessment of hepatitis B in high risk people of Gachsaran city, Iran


  • Mona Khajavian Department of Microbiology, Yasooj Branch, Islamic Azad University, Yasooj, Iran
  • Asghar Sharifi Cellular and Mollecular Center, Yasuj University of Medical Science, Yasuj, Iran



Hepatitis B, High risk group, Molecular, Seroprevalance


Background: Hepatitis B virus (HBV) is a major health problem throughout the world. The aim of this study determines the rate of prevalence of molecular and Seroepidemiological hepatitis B infections high risk populations in the Gachsaran city, according to factors such as age, sex, employment status, educational status etc.

Methods: In a descriptive and analytical study, blood samples have been collected from 500 high risks individuals, from February 2015 to July 2016 in Gachsaran. The serum samples were tested by ELISA and PCR method was used to confirm the diagnosis. Data were analyzed by SPSS statistical program.

Results: HBsAg was detected in 5 out of the 500 individuals, giving an overall prevalence of 1%. All the positive samples were in males. The rate of infection among the individuals with a history of unprotected sexual contact was 8% and was 0% among the individuals who experienced a needle stick. Four out of the five infected persons with hepatitis didn’t receive any vaccination and one of them received only one dose of vaccine.

Conclusions: The results showed 1% infection at high-risk groups in the Gachsaran city. Age rising, maleness, unemployment, low educational level and suspicies sexual partners have been the factors of increasing HBV infection prevalence. Full vaccination has a strong and meaningful relationship with hepatitis B in the target groups, which requires all people at risk to be vaccinated completely. Government cooperation to identify and treat injecting drug users and encourage them to follow the preventive methods is beneficial.


WHO - World Health Organization. Hepatitis B fact sheet number 204/WHO. (Revised October 2000). Available: ( inf.fs/ en/fact204.html.

Mahoney FJ. Update on diagnosis, management and prevention of Hepatitis B virus infection. Clin Microbiol Rev. 1999;12:351-66.

Vahid T, Alavian SM, Kabir A, Kafaee J, Yektaparast B. Hepatitis B Prevalence and Risk Factors in Blood Donors in Ghazvin, IR. Iran. Hepat Mon. 2005;5:117-22.

Bagheri Lankarani K, Saberi Froozi M, Nabipoor I, Fattahi F, Sarafrazyazdi M, Malekzadeh R. Re-assessment of the role of hepatitis B and C viruses in southern Iran. Iran J Med Sci. 1999;24:117-21.

Farzadegan H, Shamszad M, Noori-Arya K. Epidemiology of viral hepatitis among Iranian population--a viral marker study. Ann Acad Med Singapore. 1980;9:144-8.

Alavian SM. Hepatitis B virus infection in Iran; Changing the epidemiology. Iran J Clin Infect Dis. 2010;5:51-61.

Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378:571-83.

Abdel-Hamid M, Ezzat S, El-Kafrawy S, Abdel-Latif S, El-Daly M, Turner P, et al. Viral, genetics and environmental risk factors for hepatocellular carcinoma in Egypt. Int J Virol. 2005;1:57.

Yuan H, Lee WM. Update of chronic hepatitis B. Curr Opin Gastroenterol. 2011;27:217-23.

Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L. Hepatitis B: Epidemiology and prevention in developing countries. World J Hepatol. 2012:27:74-80.

Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;9:2212-9.

Alavian SM, Hajariazdeh B, AhmadzadAsl M, Kabir A, Bagheri Lankarani K. Hepatitis B virus infection in Iran: a systematic review. Hepat Mon. 2008;8:281-94.

Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007;16:403-6.

Esteghamati A, Keshtkar AA, Nadjafi L, Gouya MM, Salaramoli M, Roshande GH, Yaghini F. Hepatitis B vaccination coverage among Iranian children aged 15–26 months in 2006. East Mediterr Health J. 2011;17:19-26.

Fathimoghaddam F, Hedayati-Moghaddam MR, Bidkhori HR, Ahmadi S, Sima HR. The prevalence of hepatitis B antigen-positivity in the general population of Mashhad, Iran. Hepat Mon. 2011;1:346-50.

Poorolajal J, Zali MR, Mohammad K, Farhadi A, Masjedi MR, Zargar A, et al. Epidemiology of hepatitis B in the Islamic Republic of Iran. East Mediterr Health J. 1996;2: 290-8.

Alavi SM, Behdad F. Seroprevalence study of hepatitis C and hepatitis B virus among hospitalized intravenous drug users in Ahvaz, Iran (2002–2006). Hepat Mon. 2010;10:101-4.

Khamisipour GR, Tahmasebi R. Prevalence of HIV, HBV, HCV and syphilis infection in high risk groups of Bushehr Province. Iranian South Med J. 2000;1:53-59.

Shekhar HU, Kabir Y, Hossain M, Uddin M, E-Jannat KK, Hossain S, et al. Blood transfusion-mediated viral infections in thalassemic children in Bangladesh. J Med Sci. 2007;7:131-5.

Gharehbaghian A, Abolghasemi H, TabriziNamini M. Status of blood transfusion services in Iran. Asian J Transfus Sci. 2008;2:13-7.

Khedmat H, Fallahian F, Abolghasemi H, Alavian SM, Hajibeigi B, Miri SM, et. Seroepidemiologic study of hepatitis B virus, hepatitis C virus, human immunodeficiency virus and syphilis infections in Iranian blood donors. Pak J Biol Sci. 2007;10:4461-6.




How to Cite

Khajavian, M., & Sharifi, A. (2017). Assessment of hepatitis B in high risk people of Gachsaran city, Iran. International Journal of Research in Medical Sciences, 5(3), 888–892.



Original Research Articles